Japan approves Dupixent for adults with bullous pemphigoid
CURRENT BRIEF VERSION: Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for adults with bullous pemphigoid, giving Regeneron and Sanofi the first targeted medicine for the disease in that market. The March 24, 2026, announcement said the approval covers adults with moderate-to-severe disease and was based on the pivotal LIBERTY-BP ADEPT study, where more than four times as many patients on dupilumab achieved sustained disease remission through Week 36 versus placebo. Sanofi also said Dupixent is now approved for bullous pemphigoid in Japan and the US, extending the drug’s reach in a rare, high-burden autoimmune blistering disease. The approval also comes as Regeneron continues to broaden other flagship brands, including a recent FDA label expansion for Eylea HD allowing dosing intervals up to 20 weeks in wet age-related macular degeneration and diabetic macular edema after one year of response — a reminder that the company is advancing both immunology and ophthalmology franchises in parallel. (sanofi.com)
Why it matters: For veterinary professionals, this is a useful signal in translational dermatology and immunology rather than a practice-changing animal health development. Bullous pemphigoid is rare in companion animals, but the approval adds to evidence that blocking IL-4 and IL-13 signaling can alter disease course in autoimmune and pruritic skin disease, with steroid-sparing potential that may be relevant to how clinicians think about future biologic development across species. It also reinforces how large human drugmakers are expanding established biologics across narrower indications — and, in Regeneron’s case, continuing to optimize other mature brands with convenience-focused label updates such as extended Eylea HD dosing — a pattern worth watching for spillover into veterinary R&D and specialty referral care. (sanofi.com)
What to watch: Watch for European regulatory action on Dupixent in bullous pemphigoid, fuller publication of ADEPT data, and continued pipeline execution from Regeneron, including an April 2026 FDA action date for the Eylea HD prefilled syringe under a CMC prior-approval supplement review. (fortune.com)